Research Output per year
Personal profile
Education/Academic qualification
Doctor of Philosophy (PhD), The University of Western Australia
Bachelor of Medicine and Bachelor of Surgery (MBBS), Cairo University
External positions
Medical Oncologist, St John of God Subiaco Hospital
Dec 2015 → …Medical Oncologist, Linear Clinical Research
Apr 2014 → …Medical Oncologist, Sir Charles Gairdner Hospital
27 Jan 2014 → …Keywords
- Medicine and Pharma
- Gynaecological Cancers
- Melanoma
- Clinical Trials
- Tumour Immunology
- Immunotherapy
Fingerprint Dive into the research topics where Tarek Meniawy is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 32 Similar Profiles
Neoplasms
Medicine & Life Sciences
Melanoma
Medicine & Life Sciences
DNA
Medicine & Life Sciences
Drug Therapy
Medicine & Life Sciences
Ovarian Neoplasms
Medicine & Life Sciences
Survival
Medicine & Life Sciences
Meta-Analysis
Medicine & Life Sciences
Non-Small Cell Lung Carcinoma
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output 2010 2019
Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma
Calapre, L., Giardina, T., Robinson, C., Reid, A. L., Al-Ogaili, Z., Pereira, M. R., McEvoy, A. C., Warburton, L., Hayward, N. K., Khattak, M. A., Meniawy, T. M., Millward, M., Amanuel, B., Ziman, M. & Gray, E. S., Feb 2019, In : Molecular Oncology. p. 171-184 14 p.Research output: Contribution to journal › Article
Open Access
Melanoma
DNA
Mutation
Neoplasms
Biopsy
1
Citation
(Scopus)
Monitoring melanoma recurrence with circulating tumor DNA: A proof of concept from three case studies
McEvoy, A. C., Pereira, M. R., Reid, A., Pearce, R., Cowell, L., Al-Ogaili, Z., Khattak, M. A., Millward, M., Meniawy, T. M., Gray, E. S. & Ziman, M., 4 Jan 2019, In : Oncotarget. 10, 2, p. 113-122 10 p.Research output: Contribution to journal › Article
Open Access
Melanoma
Recurrence
DNA
Neoplasms
Physiologic Monitoring
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data
The HGSC CRS Collaborative Network, 19 May 2019, In : Gynecologic Oncology.Research output: Contribution to journal › Article
Open Access
Meta-Analysis
Carcinoma
Drug Therapy
Disease-Free Survival
Biomarkers
A Phase 1B Study of the Anti-PD-1 Monoclonal Antibody, Tislelizumab, in Combination with the Parp Inhibitor, Pamiparib, in Advanced Solid Tumors
Friedlander, M., Meniawy, T., Markman, B., Mileshkin, L. R., Harnett, P., Millward, M., Lundy, J., Freimund, A. E., Norris, C., Wu, J., Paton, V., Wang, L. & Gao, B., Aug 2018, In : Asia-Pacific Journal of Clinical Oncology. 14, p. 58-59 2 p.Research output: Contribution to journal › Abstract/Meeting Abstract
A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.
Friedlander, M., Meniawy, T., Markman, B., Mileshkin, L. R., Harnett, P., Millward, M., Lundy, J., Freimund, A. E., Norris, C., Mu, S., Paton, V., Wang, L. & Gao, B., 10 Feb 2018, In : Journal of Clinical Oncology. 36, 5, 2 p.Research output: Contribution to journal › Abstract/Meeting Abstract